Company intelligence / Profile preview
Zhaoke Pharmaceutical
Guangzhou, Guangdong, Chinazkoph.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
The company has multiple products in late-stage development and has received marketing authorization for Bimatoprost Timolol eye drop (晶贝莹®) in February 2023. Their NVK002 for myopia received NMPA acceptance for review in January 2025. They also launched azelastine hydrochloride eye drops (Shunmin®) in March 2025.
- Therapeutic areas
- ImmunologyOphthalmology
- Modalities
- Small molecule drugsSynthetic peptidesMonoclonal antibodiesInterferons
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
VylumaKwangdong PharmaceuticalVisusSeefunge Pharmaceutical Technology Co., Ltd.
Beyond the preview
Go deeper on Zhaoke Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhaoke Pharmaceutical.